All In Biotech

Drug Trial Radar · NCT06719973

Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

An Open Label, Multicenter, Phase 1 Study of the PARP1 Inhibitor M9466 in Combination With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

Last checked: Nov 20, 2026Latest source record: Jun 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

May 14, 2025

Primary completion

May 14, 2025

Study completion May 14, 2025

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Dec 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic, and preliminary clinical activity of M9466 in combinations with carboplatin in advanced or metastatic refractory solid tumor and with the standard of care (carboplatin, etoposide, and atezolizumab) in treatment-naïve ES-SCLC. The results will support any investigation of carboplatin-based combination anticancer treatments with M9466 as well as the selection of a RP2D of M9466 in combination with carboplatin, etoposide, and atezolizumab for a subsequent ES-SCLC study.

Conditions

  • Advanced Solid Tumors

Interventions

  • M9466Drug

    Participants will receive an escalating doses of M9466 orally in 21-day cycles until disease progression, intolerable toxicity, death, withdrawal of study or study consent, lost to follow-up, or end of study.

  • CarboplatinDrug

    Carboplatin will be administered intravenously on Day 1 of each 21-day cycle.

  • EtoposideDrug

    Etoposide will be administered intravenously as per standard of care.

  • AtezolizumabDrug

    Atezolizumab will be administered intravenously as per standard of care.

  • M9446Drug

    M9446 dose will be further investigated in Module 2 Part A of the study.

  • M9446Drug

    M9446 recommended Dose for Expansion (RDE) will be further investigated in Module 2 Part B of the study.

  • CarboplatinDrug

    Carboplatin will be administered intravenously as per standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Module 1 and Module 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Treatment Related TEAEsTime frame: Time from signing Informed Consent Form (ICF) up to 30 days after end of study intervention (approximately assessed up to 24 months)
  2. Module 1 and Module 2: Number of Participants with Dose-limiting Toxicity (DLT)Time frame: Day 1 up to Day 21 of Cycle 1 (each cycle is of 21 days)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.